Oncolytic Viruses-immunotherapeutics on the Rise

Overview

Journal J Mol Med (Berl)

Specialty General Medicine

Date 2016 Aug 6

PMID 27492706

Citations 35

Authors

Brian A Keller

John C Bell

Affiliations

Soon will be listed here.

Abstract

The oncolytic virus (OV) field has entered an exciting period in its evolution in which our basic understanding of viral biology and anti-cancer potential are being actively translated into viable therapeutic options for aggressive malignancies. OVs are naturally occurring or engineered viruses that are able to exploit cancer-specific changes in cellular signaling to specifically target cancers and their microenvironment. The direct cytolytic effect of OVs on cancer cells is known to release antigens, which can begin a cascade of events that results in the induction of anti-cancer adaptive immunity. This response is now regarded as the most critical mechanism of OV action and harnessing it can lead to the elimination of distant micrometastases as well as provide long-term anti-cancer immune surveillance. In this review, we highlight the development of the OV field, why OVs are gaining an increasingly elevated standing as members of the cancer immunotherapy armamentarium, and finally, ongoing clinical studies that are aimed at translating unique OV therapies into approved therapies for aggressive cancers.

Citing Articles

An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma.

Reale A, Gatta A, Shaik A, Shallak M, Chiaravalli A, Cerati M J Transl Med. 2024; 22(1):862.

PMID: 39334370 PMC: 11430576. DOI: 10.1186/s12967-024-05650-5.

Oncolytic virus V937 in combination with PD-1 blockade therapy to target immunologically quiescent liver and colorectal cancer.

Tran T, Grein J, Selman M, Annamalai L, Yearley J, Blumenschein W Mol Ther Oncol. 2024; 32(2):200807.

PMID: 38745749 PMC: 11090910. DOI: 10.1016/j.omton.2024.200807.

Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers.

Vannini A, Parenti F, Forghieri C, Barboni C, Zaghini A, Campadelli-Fiume G Front Mol Biosci. 2023; 10:1149973.

PMID: 37251078 PMC: 10213976. DOI: 10.3389/fmolb.2023.1149973.

Intravesical oncolytic virotherapy and immunotherapy for non-muscle-invasive bladder cancer mouse model.

Smelser W, Wang J, Ogden K, Chang S, Kirschner A BJU Int. 2023; 132(3):298-306.

PMID: 36961272 PMC: 10518025. DOI: 10.1111/bju.16012.

Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma.

Cerqueira O, Antunes F, Assis N, Cardoso E, Clavijo-Salomon M, Domingues A Front Mol Biosci. 2022; 9:777775.

PMID: 35495634 PMC: 9048901. DOI: 10.3389/fmolb.2022.777775.

References

McCart J, Ward J, Lee J, Hu Y, Alexander H, Libutti S . Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001; 61(24):8751-7. View

Liu B, Robinson M, Han Z, Branston R, English C, Reay P . ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003; 10(4):292-303. DOI: 10.1038/sj.gt.3301885. View

Kim J, Oh J, Park B, Lee D, Kim J, Park H . Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006; 14(3):361-70. DOI: 10.1016/j.ymthe.2006.05.008. View

Vlahava V, Eliopoulos A, Sourvinos G . CD40 ligand exhibits a direct antiviral effect on Herpes Simplex Virus type-1 infection via a PI3K-dependent, autophagy-independent mechanism. Cell Signal. 2015; 27(6):1253-63. DOI: 10.1016/j.cellsig.2015.03.002. View

Quetglas J, Labiano S, Aznar M, Bolanos E, Azpilikueta A, Rodriguez I . Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade. Cancer Immunol Res. 2015; 3(5):449-54. DOI: 10.1158/2326-6066.CIR-14-0216. View

Zhang Q, Liang C, Yu Y, Chen N, Dandekar T, Szalay A . The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genomics. 2009; 282(4):417-35. PMC: 2746888. DOI: 10.1007/s00438-009-0475-1. View

Spain L, Diem S, Larkin J . Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016; 44:51-60. DOI: 10.1016/j.ctrv.2016.02.001. View

Chow L . Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. Am Soc Clin Oncol Educ Book. 2013; . DOI: 10.14694/EdBook_AM.2013.33.e280. View

Parato K, Breitbach C, Le Boeuf F, Wang J, Storbeck C, Ilkow C . The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther. 2011; 20(4):749-58. PMC: 3321594. DOI: 10.1038/mt.2011.276. View

10.

Ilkow C, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S . Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat Med. 2015; 21(5):530-6. DOI: 10.1038/nm.3848. View

11.

Yan Y, Li S, Jia T, Du X, Xu Y, Zhao Y . Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity. Tumour Biol. 2015; 36(6):4535-43. DOI: 10.1007/s13277-015-3098-7. View

12.

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

13.

Brun J, McManus D, Lefebvre C, Hu K, Falls T, Atkins H . Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther. 2010; 18(8):1440-9. PMC: 2927055. DOI: 10.1038/mt.2010.103. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Brown S, MacLean A, McKie E, Harland J . The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34. J Virol. 1997; 71(12):9442-9. PMC: 230249. DOI: 10.1128/JVI.71.12.9442-9449.1997. View

16.

Arulanandam R, Batenchuk C, Angarita F, Ottolino-Perry K, Cousineau S, Mottashed A . VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell. 2015; 28(2):210-24. DOI: 10.1016/j.ccell.2015.06.009. View

17.

Huang J, Zhang S, Choi K, Choi I, Kim J, Lee M . Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther. 2009; 18(2):264-74. PMC: 2839296. DOI: 10.1038/mt.2009.205. View

18.

Carew J, Kooby D, Halterman M, Kim S, Federoff H, Fong Y . A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol Ther. 2001; 4(3):250-6. DOI: 10.1006/mthe.2001.0448. View

19.

Li S, Zhu M, Pan R, Fang T, Cao Y, Chen S . The tumor suppressor PTEN has a critical role in antiviral innate immunity. Nat Immunol. 2015; 17(3):241-9. DOI: 10.1038/ni.3311. View

20.

Breitbach C, Burke J, Jonker D, Stephenson J, Haas A, Chow L . Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011; 477(7362):99-102. DOI: 10.1038/nature10358. View